Cite
Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods
MLA
Saber, Wael, et al. “Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods.” Biology of Blood & Marrow Transplantation, vol. 20, no. 10, Oct. 2014, pp. 1566–72. EBSCOhost, https://doi.org/10.1016/j.bbmt.2014.06.010.
APA
Saber, W., Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., & Cutler, C. S. (2014). Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. Biology of Blood & Marrow Transplantation, 20(10), 1566–1572. https://doi.org/10.1016/j.bbmt.2014.06.010
Chicago
Saber, Wael, Jennifer Le Rademacher, Mikkael Sekeres, Brent Logan, Moira Lewis, Adam Mendizabal, Eric Leifer, et al. 2014. “Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods.” Biology of Blood & Marrow Transplantation 20 (10): 1566–72. doi:10.1016/j.bbmt.2014.06.010.